María José F. L.
- Country
- Spain
- Department
- #7008: Hematología
Research Overview
- Evaluation of Bomedemstat Versus Best Available Therapy in Essential Thrombocythemia Patients with Hydroxyurea Intolerance or Inadequate Response
- A Phase 3 Randomized Open-Label Study of Imetelstat Versus Best Available Therapy in Intermediate-2 or High-Risk Myelofibrosis Refractory to JAK-Inhibitors
- Evaluation of Navtemadlin Versus Best Available Therapy in Myelofibrosis Patients Refractory to JAK Inhibitors
Data & Insights
Has run more than one trial at 44 of 162 partner sites.
Specializations
Hematologic Disorders
This investigator specializes in treating complex blood disorders, with particular emphasis on Essential Thrombocythemia and Myelofibrosis. Their research focus includes managing patients who have shown inadequate response to conventional treatments.
- Essential Thrombocythemia Management
- Myelofibrosis Treatment Strategies
- JAK-inhibitor Resistant Cases
The investigator evaluates novel therapeutic approaches for patients with treatment-resistant myeloproliferative conditions.
Treatment Resistance
The investigator has developed expertise in addressing treatment-resistant blood disorders, particularly focusing on patients who have not responded adequately to standard therapies like hydroxyurea and JAK-inhibitors.
- Alternative Treatment Strategies
- Best Available Therapy Optimization
- Novel Therapeutic Approaches
Their work encompasses evaluating innovative treatment options for patients with limited therapeutic alternatives.
Clinical Outcomes
The investigator focuses on measuring and improving patient outcomes in hematologic malignancies, with particular attention to survival rates and durable clinical responses.
- Overall Survival Assessment
- Durable Response Evaluation
- Treatment Efficacy Monitoring
Their research emphasizes comparative effectiveness of various treatment approaches in challenging hematologic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.